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tient visit for 12 months. Annual average visit days of outpatients were 37. Annual
overall costs per patient were 13.4million Koreanwon (KRW), of which 10.5million
KRW (78.6%)was drug costs because of costly TNF antagonist. Inspection cost came
next with 5.6% of the total costs, followed by hospitalization cost (4.6%), operation
cost (4.0%), and doctor’s fee (3.2%).Mean out-of–pocket expenditurewas 3.7million
KRW, 27.1% of the overall costs. As age increased, so did the total costs. Male,
medical aid, and patients with hospitalization or surgery were associated with
significantly higher costs than female, health insurance, and inexperienced pa-
tients of hospitalization or surgery respectively(p0.05). CONCLUSIONS: Direct
medical costs per capita of RA patients receiving TNF antagonist in Koreawere 13.4
million KRW. The economic burden of RA patients is strongly influenced by TNF
antagonist.
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EVALUATING THE ASSOCIATION BETWEEN SERUM URIC ACID LEVEL AND
HEALTH CARE COSTS IN PATIENTS WITH GOUT
Cheng IN1, Duffin M1, Pulicharam JS1, Tong G2, Aranda GA, J2
1HealthCare Partners Medical Group, Torrance, CA, USA, 2Takeda Pharmaceuticals North
America, Inc, Deerfield, IL, USA
OBJECTIVES: To describe the association between serum uric acid (sUA) levels and
gout-related healthcare utilization and costs. METHODS: A retrospective analysis
was conducted using a database from a regional managed care organization. Pa-
tients with primary gout were included in the study if they met the following
criteria between 2006 and 2007: (1) age 18; (2) 1 diagnosis of gout (ICD-9-CM
274.xx), or 1 prescription gout-related medications (colchicine, allopurinol, pro-
benecid); (3) 12 months continuous eligibility pre- and post- either the first gout
diagnosis or first pharmacy claim date (index date). Patients with cancer diagnoses
were excluded. Patients were classified into three sUA levels based on the mea-
surement taken on the date closest to the index date: 6.0 mg/dL, 6.0- 8.99 mg/dL,
and 9.0 mg/dL. Healthcare costs in the12 months post index period were com-
pared across the three sUA levels using Kruskal-Wallis tests. RESULTS: A total of
1,622 patients were identified; 374 (23.0%) had an sUA 6.0 mg/dL, 788 (48.0%) had
an sUA of 6.0-8.99 mg/dL, and 470 (29.0%) had an sUA 9.0 mg/dL. The mean
gout-related healthcare costs were $217(standard deviation [SD] $631), $426 (SD
$4330), and $647(SD $4274) for patients with sUA 6.0 mg/dL, 6.0- 8.99 mg/dL, and
9.0 mg/dL, respectively (p0.0001). Statistically significant differences were also
detected in the gout-related outpatient costs, gout-related emergency department
costs, and gout-related prescription costs among the three groups. CONCLUSIONS:
Our results showed that there is a positive association between sUA levels and
gout-related healthcare utilization and costs. Lowering andmaintaining sUA levels
6 mg/dL may lead to lower gout-related healthcare costs and decrease gout-
related utilization of services. Further study is warranted.
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IMPACT OF TREATMENT PERSISTENCE AND COMPLIANCE ON HEALTH CARE
RESOURCE UTILISATION AND TOTAL HEALTH CARE COST IN POST
MENOPAUSAL WOMEN PRESCRIBED ORAL BISPHOSPHONATES – A
RETROSPECTIVE STUDY USING THE GENERAL PRACTICE RESEARCH DATABASE
(GPRD)
Murray-Thomas T, Patel D, Williams T, van Staa T
Medicines and Healthcare Products Regulatory Agency, London, UK
OBJECTIVES: Oral bisphosphonate therapy reduces the risk of fractures and asso-
ciated morbidity in women with post-menopausal osteoporosis. This study evalu-
ated how failure to persist and comply with oral bisphosphonates impacts on the
use of health care services and costs. METHODS: Retrospective cohort analysis of
6,870 womenwith incident bisphosphonate prescribing in UK primary care. Persis-
tence was defined as no gaps in refill of30 days; compliance wasmeasured using
medication possession ratio (MPR 80). The impact of non-persistence and non-
compliance on the intensity of health service use (HSU) in the 24-month period
following treatment was analyzed using negative binomial regression; the impact
on costs was analysed using gamma regression. Primary care data, linked Hospital
Episode Statistic data andnationally available prescribing andhealth care cost data
were used. RESULTS: Persistence and compliance in the 24-month period was
32.4% and 59.2% respectively. In multivariable analysis, non-persistent patients
had a 15% increased frequency of primary care contact (incident rate ratio (IRR):
1.15; 95% CI: 1.12-1.19) and a 92% increased (IRR: 1.92; 95% CI: 1.74-2.12) frequency
of inpatient hospitalisation for any cause. The IRR of osteoporosis-related hospi-
talisations for non-persistent patients was 2.23 (95% CI: 1.66-2.98). Non-compliant
patients had a 5% increased frequency of primary care contact (IRR: 1.05; 95% CI:
1.02-1.18), a 55% increased (IRR:1.55; 95% CI: 1.41-1.69) frequency of all-cause inpa-
tient hospitalisation and a 37% increased frequency of osteoporosis-related hospi-
talisations (IRR: 1.37; 95% CI: 1.07 1.75). Average total health care cost was signif-
icantly higher among non-persistent (£3,557 [95% CI: £3,372-£3,742]) than
persistent patients (£2,540 [95% CI: £2,370- £2,710]). Among non-compliant pa-
tients, average total health care costs was £3,592 (95% CI: £3,369 –3,816) compared
to compliant patients- £3,028 (95% CI: £2,853- £3,202)- a cost difference of £564.
CONCLUSIONS: Suboptimal persistence and compliance with oral bisphospho-
nates is associated with significant increases in HSU and costs.
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FRACTURE-RELATED TREATMENT COSTS ATTRIBUTABLE TO PROTON PUMP
INHIBITOR USE IN OSTEOPOROSIS PATIENTS
McGuire M1, Choi IS1, Suh K1, Kim CM2, Barone J1
1Rutgers University, Piscataway, NJ, USA, 2Catholic University School of Medicine, Seoul, South
Korea
OBJECTIVES: To estimate the differences in fracture-related treatment costs (FTC)
between osteoporosis patients with and without proton pump inhibitor (PPI) use.
METHODS: Data from the 2001-2008 Medical Expenditure Panel Surveys was used
to identify osteoporosis patients50 years old through an ICD-9-CM code of 733 or
clinical classification code of 206. Patients were categorized into two groups based
on PPI use. Considered medications included osteoporosis agents (bisphospho-
nates, hormone therapy, and raloxifene) and corticosteroids (excluding topicals).
Fractures were identified based on ICD-9-CM codes 804-829. Mean of treatment
costs were calculated with bootstrap confidence interval due to skewed costs. FTC
were estimated using generalized linear model with log link function and gamma
distribution. First, FTC for patients treated with PPI were predicted using the esti-
mated coefficients from patients without PPIs using a generalized linear model
with adjustments for patient characteristics, medication use, and comorbidities.
Second, attributable costs to the use of PPI were estimated by the difference be-
tween predicted and observed costs for PPI users. Treatment costs for one year
were calculated and converted to 2009 U.S. dollar using appropriate price indices.
RESULTS:We identified 4,979 patients with osteoporosis. PPI use was found in 970
patients and in 4,009 it was not. Unadjusted cost differences showed patients with
PPI use had similar osteoporosis-related costs (excluding fracture costs) to patients
without ($883 vs. $798). However, patients treated with PPI had higher FTC by $335
thanpatientswithout PPI use ($709 vs. $374). After adjusting for the study variables,
PPI use was associated with an increase in FTC by 63% when compared to patients
not taking PPIs. CONCLUSIONS: Use of PPIs increases the economic burden of
osteoporosis patients primarily due to fracture-related costs. Additional studies
are warranted to further explore the cost attributable to fracture due to use of PPIs
in osteoporosis patients.
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HEALTH CARE RESOURCES UTILIZATION IN THE MANAGEMENT OF JUVENILE
IDIOPATHIC ARTHRITIS: ANALYSES WITH THE RAMQ DATABASE
Lachaine J1, Beauchemin C1, Martel MJ2, Goyette A2
1University of Montreal, Montreal, QC, Canada, 2Abbott Laboratories, St-Laurent, QC, Canada
OBJECTIVES: Juvenile idiopathic arthritis (JIA) is a chronic autoimmune inflamma-
tory disease in childhood affecting about 1 in 1000 children. The objectives of this
study were to analyze drug utilization in JIA, particularly the use of anti-TNFs and
to estimate health care resources utilization associated with JIA management.
METHODS: A retrospective prescription claims analysis of a random sample of
patients from the Régie de l’assurance maladie du Québec (RAMQ) provincial
health plan (Québec, Canada) database was conducted. Data of patients with a
diagnosis of rheumatoid arthritis and aged less than 20 years were obtained for the
period from January 1998 to December 2009. Healthcare resources consumed by
patients with JIA were identified in terms of visits to physicians, physician’s inter-
ventions, arthritis related medications, other medications, emergency visits and
hospitalizations. RESULTS: Data were obtained from the RAMQ for a total of 995
patientswith amean age of 11.4 years (SD5.2). Anti-TNFswere used by 32 patients
(3.2%). In the year following initiation of anti-TNF treatment, reductions in all
healthcare resources used were observed, the greatest decreases being for the
average number of medical visits per patient (before/after: 14.7 vs. 8.1) and average
number of physician’s interventions per patient (before/after: 5.8 vs. 3.3). Decreases
in costs of all healthcare resources were also seen and costs associated with hos-
pitalization decrease significantly by an average of CAN$1,356 per patient (p0.05)
in the year following the initiation of anti-TNF treatment. CONCLUSIONS: Anti-
TNFs have demonstrated significant clinical benefits and on other aspects of JIA
patients’ lives, such as functionality, school performance, or health-related quality
of life. Results of these claims analyses showed that the use of anti-TNFs was
associated with decreases in healthcare utilization in the year following initiation
of treatment which translated in reductions in the cost of healthcare resources for
JIA patients.
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COST-EFFECTIVENESS ANALYSIS
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OBJECTIVES: To determine the costeffectiveness of abatacept or infliximab in
patients with rheumatoid arthritis (RA) with inadequate response tomethotrexate
(IRMTX) in Venezuela. METHODS: Adapting a previously validated model, dy-
namic simulation techniques and clinical data frompublished literaturewere used
to compare the clinical events, quality of life, and direct medical costs of abatacept
and infliximab to MTX. The prevalence of the disease and the demographic char-
acteristics for Venezuela, were used to assign a pretreatment score relative to the
Health Assessment Questionnaire (HAQ). Then, HAQ scores were projected over
time according to the efficacy of each treatment. The costs associated with each
treatment and the disease were calculated from private and public hospitals, for a
reference patient weighting 60 kg, and validated with a group of experts. The re-
sults of the model were analyzed over a 10year time horizon using the payer’s
perspective, and a3% annual discount. Univariate and probabilistic sensitivity
analyses for relevant parameters were performed to assess the robustness of the
results of themodel. RESULTS:A hypothetical cohort of 1,000 patients with RA and
IR MTX in Venezuela,followed for 10 years, resulted in mean treatment costs of:
U$5,126, U$57,824, andU$27,842 dollars, forMTX, abatacept, and infliximab,respec-
tively. Total direct medical costs(discounted) per patient were U$ 50,441 (48,819
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52,448) for MTX, U$ 93,992 (89,36698,982) for abatacept, and $73,100 (68,539
81,877) for infliximab. The total QALYs gained(discounted) by MTX, abatacept, and
infliximab during the same period were: 2.96 (2.893.03), 4.05 (3.854.30) and 3.26
(3.163.39) respectively. The Incremental Cost-Effectiveness Ratio was U$ 39,980
(36,64945,011) for Abatacept compared to MTX compared to U$ 77,790
(62,36998,124) per QALY gained with infliximab. CONCLUSIONS: The use of
abatacept is more costeffective than the use of infliximab, both compared to
MTX, in patients with Rheumatoid Arthritis with IR MTX in Venezuela.
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COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT IN THE TREATMENT OF
RHEUMATOID ARTHRITIS IN MEXICO
Vargas-Valencia J1, Sotelo-Guzmán M1, Mould-Quevedo JF2, Muciño-Ortega E3,
Galindo-Suarez RM3
1Econopharma Consulting S. A. de C. V., Mexico City, Mexico, 2Pfizer, New York, NY, USA,
3Pfizer, Mexico City, Mexico
OBJECTIVES: Rheumatoid Arthrtis (RA) critically impair the quality of life of pa-
tients. Biologic treatments represent a therapeutic alternative for patients who
failed disease-modifying antirheumatic drugs. However, their high cost is a chal-
lenge for clinicians and decision makers. The aim of this study was to assess the
cost-effectiveness of biologic alternatives to treat RA currently available in Mexico,
froman institutional perspective.METHODS:Adecision-treemodelwas developed
to simulate the clinical course of patients treated with etanercept (reference treat-
ment), adalimumab, infliximab, tocilizumab or rituximab as first-line therapies, as
well as associated costs over one-year period. Therapy continuation or treatment
switch was evaluated at month 6. Effectiveness measures were: proportion of pa-
tients achieving 70% improvement in both, tender or swollen joint counts following
the American College of Rheumatology (ACR70) criteria and quality adjusted life
years gained (QALY=s). Costs considered included: biologics, concomitant drugs,
medical follow-up and side effects management. Clinical response of alternatives
was extracted from published literature, while costs were collected from Instituto
Mexicano del Seguro Social (IMSS) official databases. Probabilistic sensitivity anal-
yseswere done throughMonte Carlo Simulation second-order approach. RESULTS:
The effectiveness of therapies resulted in [ACR70, QALY=s]: etanercept [31.3%, 0.79];
adalimumab [18.1%, 0.77]; infliximab [12.8%, 0.73]; tocilizumab [21.1%, 0.77] and
rituximab [11.9%, 0.75]. Expectedmean costs per patient were: US$12,914.36 [95%CI
US$12,901.58-US$12,927.08]; US$15,715.06 [95%CI US$15,699.73-US$15,730.39];
US$14,479.96 [95%CI 14,465.77-US$14,494.16]; US$44,455.03 [95%CI US$44,411.53-
US$44,498.53] and US$17,267.61 [95%CI US$17,250-US$17,284.53], respectively. Et-
anercept is both, the less costly and the most effective alternative: US$31,504.80
less than tocilizumab (the most costly alternative) and 19.3% more patients meet
the ACR70 criteria regarding rituximab (the less effective alternative). Acceptability
curves showed that etanercept regardless willingness to pay would be the most
cost-effective biologic. CONCLUSIONS: Due to their lower costs and favorable ef-
fectiveness profile, etanercept is dominant over other biologic treatments in the
management of RA at IMSS.
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COST-EFFECTIVENESS ANALYSIS OF ANALGESIC THERAPY FOR
POSTOPERATIVE PAIN AFTER TOTAL HIP ARTHROPLASTY IN MEXICO
Contreras I1, Mould-Quevedo JF2, Goycochea-Robles MV1, Torres-Gonzalez R1,
Garduño-Espinosa J3
1Instituto Mexicano del Seguro Social, México City, Mexico, 2Pfizer, New York, NY, USA,
3Hospital Infantil de Mexico Federico Gómez, México City, Mexico
OBJECTIVES: Inappropriate analgesia in postoperative pain (POP) raises hospital-
ization costs and increases the burden of several surgeries with a meaningful im-
pact over patient’s quality of life. The objective of this study was to develop an
economic analysis to evaluate parecoxib, ketorolac andmorphine in the treatment
of POP in patients who underwent total hip arthroplasty from an institutional
perspective. METHODS: A cost-effectiveness analysis was developed using a
Bayesian decision-tree model, to simulate costs and effectiveness outcomes over
the postoperative hospitalization period (15 days). Comparators were multimodal
analgesics: morphine (52 mg/day) plus parecoxib (40 mg/day); morphine (52 mg/
day) plus ketorolac (90 mg/day) and morphine (57 mg/day) alone. Effectiveness
measures were: percentage of treatment response without adverse events (AE)
meeting the highest score of the patient’s global evaluation survey (excellent).
Effectiveness data and transition probabilities were collected from international
published literature. Resource use and cost data was gathered from hospital re-
cords of patients undergoing total hip arthroplasty at the Social Security Mexican
Institute (IMSS) (n89). The model was calibrated according to international phar-
macoeconomics guidelines. One-way and probabilistic sensitivity analyses were
performed with Monte Carlo Simulation second-order approach. RESULTS: Pa-
tients who received parecoxib exhibited 41% of treatment response, followed by
morphine (26%) and ketorolac (24%). Estimated costs per patient were lower with
parecoxib (US$ 5,439.30) followed by ketorolac (US$5,538.91) and morphine
(US$5,553.71). No statistical differences were found among the costs of analgesic
therapies (p0.05). Parecoxib showed a weak dominance against its competitors.
Acceptability curves showed parecoxib as themost cost-effective therapywith 95%
when willingness to pay is US$6,500. CONCLUSIONS: Results show that at the
IMSS, parecoxib is a cost-effective treatment that significantly reduces POP in pa-
tients who underwent total hip arthropasty. This information could be useful for
developing markets healthcare institutions in order to establish efficient analge-
sics improving current health outcomes.
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THE COST EFFECTIVENESS OF STRONTIUM RANELATE VERSUS RISEDRONATE,
RALOXIFENE, IBANDRONATE, ALENDRONATE AND CALCITONIN IN THE
TREATMENT OF POSTMENOPAUSAL OSTEOPOROTIC WOMEN IN TURKEY
Malhan S1, Cetin A2, Gur A3, Kavuncu V4, Tan M5
1Baskent University, Ankara, Turkey, 2Hacettepe University, Ankara, Turkey, 3Gaziantep
University, Gaziantep, Turkey, 4Kocatepe University, Afyon, Turkey, 5Servier Ilac ve Arastirma
A.S., Istanbul, Turkey
OBJECTIVES: The goal of this studywas to estimate the cost-effectiveness of stron-
tium ranelate in the treatment of postmenopausal osteoporotic women in Turkey.
METHODS: A validated Markov microsimulation model with a Turkish payer’s
perspective estimated the cost per quality-adjusted life-year (QALY) of strontium
ranelate treatment compared with risedronate, raloxifene, ibandronate, alendro-
nate and calcitonin. Markov Model was used and applied in the Treeage Pro soft-
ware over a cohort of 1000 patients in the pharmacoeconomical analysis. As for the
sensitivity analysis, theMonte Carlo Simulationwas used, applying a simulation of
10.000. Data on the effect of both treatments on fracture risk were taken from the
literature. The cost of the treatments were calculated based on Turkish reimburse-
ment systems, the indirect and intangible costs were omitted. The direct disease
costs include the amount spent for the costs associated with the outpatient, inpa-
tient, medical supplies, all the laboratory or imaging tests and the interventions
performed. The costs of the side effectswere added to all the drug costs. The official
product summaries were used for detecting the side effects of the products.
RESULTS: Strontium Ranelate provides the highest gain of quality life years and is
the superlative therapeutical choice with respect to QALY. According to it’s cost
and effectiveness value, strontium ranelate was dominant (i.e. more effective and
less costly) versus ibandronate and calcitonine for postmenopausal osteoporotic
women. The cost per QALY gained by strontium ranelate compared to ibandronate
was € 5582 and calcitonine was € 3943. Compared to alendronate, risedronate and
raloxifene, strontium ranelate was cost effective (i.e. more costly but more
effective).CONCLUSIONS:The results of this study suggest that strontium ranelate
is a cost-effective strategy, in a Turkish setting, for the treatment of postmeno-
pausal osteoporotic women.
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COST-EFFECTIVENESS OF ABATACEPT OR INFLIXIMAB IN RHEUMATOID
ARTHRITIS IN COLOMBIA
Alfonso-Cristancho R1, Aiello EC2, Roa CN3
1University of Washington, Seattle, WA, USA, 2Bristol-Myers Squibb, Buenos Aires, Argentina,
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OBJECTIVES: Determine the costeffectiveness of abatacept or infliximab in pa-
tients with rheumatoid arthritis (RA) with inadequate response to methotrexate
(IRMTX) in Colombia. METHODS: Dynamic simulation techniques from a previ-
ously validatedmodel and clinical data from published literature were used for the
analysis. The functional disability was assessed using the Health Assessment
Questionnaire (HAQ). A HAQ score was randomly assigned pretreatment based
on the prevalence of the disease and the demographic characteristics for Colombia,
then projected over time using the efficacy results from published trials. Direct
medical costs were calculated from private and public hospitals,and the informa-
tion system of the Ministry of Social Protection (SISMED) and validated with local
experts (Exchange rate: $1,920 Colombian peso1 US Dollar). A 10year time ho-
rizon and the payer’s perspective were assumed. Costs and health outcomes were
discounted at 3% annually. Univariate and probabilistic sensitivity analyses were
performed to assess the robustness of the results of the model. RESULTS: In a
hypothetical cohort of 1,000 patients with RA  IR MTX, the costs of treatmentfor
the first year for MTX were U$794 dollars, compared to U$16,659 for abatacept and
U$17,531 for infliximab, assuming dosages for average patients below 60 kg. Addi-
tional analysis with patients over 60 kg were included in the sensitivity analysis.
After 10 years of followup the discounted total direct medical costs per patient
were U$55,998 (54,35457,776) for MTX, U$99,888 (94,694104,437) for abatacept,
and $79,174 (75,79583,899)for infliximab. The total number of QALYs gained (dis-
counted) by MTX, abatacept, and infliximab were: 2.88 (2.792.95), 3.94 (3.794.09)
and 3.17 (3.093.27) respectively. The calculated ICERs for abatacept and infliximab
compared to MTX were U$ 37,513 (35,22139,909) and U$75,873 (62,825103,132)
per QALY gained, respectively. CONCLUSIONS: In patients with RA  IR MTX in
Colombia, the use of abatacept is more cost-effective than the use of infliximab,
both compared to MTX.
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COST-EFFECTIVENESS MODELING IN OSTEOPOROSIS: A SYSTEMATIC
LITERATURE REVIEW AND OVERVIEW
Smolen HJ, Myers JA, Smolen LJ
Medical Decision Modeling Inc., Indianapolis, IN, USA
OBJECTIVES: To conduct a structured review of the recent osteoporosis cost-effec-
tiveness modeling literature and provide an overview of their methodologies and
approaches.METHODS:A detailed systematic reviewwas performed of the follow-
ing literature databases: MEDLINE, MEDLINE In-Process, EMBASE, Cochrane, HEED,
NHSEED, EconLit, and googlescholar. Using pre-selected inclusion/exclusion crite-
ria relevant studies published since January 2005 were identified. Relevant infor-
mation fromeach identified studywas extracted according to a predefined grid and
essential features of each osteoporosis cost-effectiveness model were recorded.
RESULTS: Forty-eight relevant and recently published osteoporosis cost-effective-
ness models were identified. Model structures were cohort Markov (56%) and indi-
vidualized microsimulations (44%). Most models (35) used a lifetime timeframe
(i.e., death or age 100). The primary interventions investigated were bisphospho-
nates (79%), raloxefine (15%), and hormone replacement therapy (10%). In 98% of
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